Logo
x

Search

Subscribe Now

astraZeneca

AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Secures the US FDA’s Approval for Mantle Cell Lymphoma (MCL)

AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Secures the US FDA’s Approval for Mantle Cell Lymphoma (MCL)

  • January 20, 2025
AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated NSCLC

AstraZeneca and Daiichi Sankyo Report the US FDA’s BLA Acceptance of Datopotamab Deruxtecan with Priority Review for EGFR-mutated...

  • January 15, 2025
AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

  • December 23, 2024
AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer

AstraZeneca and Merck Report P-III (OlympiA) Study of Lynparza to Treat Early Breast Cancer

  • December 12, 2024
AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH 2024

AstraZeneca to Feature Data from P-III (AMPLIFY) Study of Calquence Plus Venetoclax to Treat Chronic Lymphocytic Leukaemia at ASH...

  • December 9, 2024
AstraZeneca Reports the US FDA’s sBLA Acceptance and Priority Review of Imfinzi to Treat Muscle-Invasive Bladder Cancer

AstraZeneca Reports the US FDA’s sBLA Acceptance and Priority Review of Imfinzi to Treat Muscle-Invasive Bladder Cancer

  • December 6, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.